With an eye on the lucrative U.S. market, Italy’s Angelini Pharma will acquire rare disease specialist Catalyst Pharmaceuticals and its potential blockbuster, Firdapse, for $4.1 billion. Rome-based ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. The Italian company Angelini Pharma ...

State-backed CDP Equity to have a stake in combined entity Deal comes after Chiesi's $1.9 billion buyout of U.S. KalVista Angelini aims to create global player in rare disease drugs ROME/MILAN, May 7 ...

Italian drugmaker Angelini Pharma is exploring a potential acquisition of Catalyst Pharmaceuticals Inc. as it looks at deals to expand its footprint globally, people familiar with the matter said.

Revised terms due to delayed projects, lower profits JMAT plans to return 1 billion stg to shareholders post-sale completion Jefferies analysts note revised terms better than potential deal ...

A technology has been developed that uses robots rather than humans to evaluate the performance of newly developed catalysts. By operating 45 times faster than manual work while also improving ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Women exited the U.S. labor force in record numbers in 2025. A new national survey by the ...

Topsoe, a leading global provider of advanced technology and solutions for the energy transition, is making new strides in next-generation battery material with a cobalt-free, high-voltage cathode ...

If there is one point of consensus among the CES 2026 keynote speakers, it is that AI is reshaping technology with a speed and scale unlike any previous technological revolution. In a live taping on ...